# US 2008/0171709 A1 · Pharmaceutical Composition Comprising An Antiviral Agent, An Antitumoral Agent Or An Antiparasitic Agent, And An Active Agent Selected Among Carveol, Thymol, Eugenol, Borneol,And Carvacrol > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2008/0171709 A1 - Document ID: US20080171709A1 - Status: Published application - Kind: A1 - Application number: 11/914,029 - Filed: 2006-05-15 - Published: 2008-07-17 - Earliest claimed: 2005-05-13 - Assignees: Advanced Scientific Developments - Inventors: Adnane Remmal - Web page: https://patentgrep.com/patent/US20080171709A1 ## CPC - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates - A61K 31/05: Phenols {(cannabinoids A61K31/658)} - A61P 31/12: Antivirals - A61P 33/00: Antiparasitic agents - A61P 33/10: Anthelmintics - A61P 35/00: Antineoplastic agents - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The invention relates to a pharmaceutical composition comprising at least one first active therapeutic substance selected among carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone and beta-ionone, as well as isomers, derivatives and mixtures thereof, and comprising at least one second active therapeutic substance that is antitumoral. The invention is for use in the field of pharmaceutics. ## Claims ### Claim at position 1 1-12. (canceled) ### Claim 13 A pharmaceutical composition comprising: at least one first therapeutically active substance selected from the group consisting of carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone, and isomers, derivatives or mixtures thereof; and at least one second therapeutically active substance which is an antitumoral agent. ### Claim 14 (depends on 13) The composition according to claim 13, wherein said at least one second therapeutically active substance is selected from the group consisting of folate antagonists, antimetabolites, alkylating agents, platinum salts, anthracyclin and intercalating agents, anti-topoisomerases, agents acting on cytoskeleton, bleomycin, asparaginase, and mixtures thereof. ### Claim 15 (depends on 14) The composition according to claim 14, wherein said at least one second therapeutically active substance is selected from the group consisting of methotrexate, 5-fluorouracil, fluorodeoxyuridine, cytosine arabinoside, 6-mercaptopurine, 6-thioguanine, mechloroethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, thiotepa, mitomycin C, aziridinylbenzoquinone (AZQ), busulfan, carmustine (BCNU), lomustine (CCNU), fotemustine, carboplatin, daunorubicin, doxorubicin or adriamycin, epirubicin, dactinomycin or actinomycin D, mitoxanthrone, amsacrine, tenoposide, etoposide, irinotecan, topotecan, vincristine, vinblastine, vindesine, vinorelbine, taxol, taxotere, and mixtures thereof. ### Claim 16 (depends on 13) The composition according to claim 13, wherein said first therapeutically active substance is thymol, carveol or carvacrol and said at least one second therapeutically active substance is selected from the group consisting of folate antagonists, antimetabolites, alkylating agents, platinum salts, anthracyclin and intercalating agents, anti-topoisomerases, agents acting on cytoskeleton, bleomycin, asparaginase, and mixtures thereof. ### Claim 17 (depends on 13) The composition according to claim 13, wherein said first therapeutically active substance is thymol, carveol or carvacrol and said at least one second therapeutically active substance is selected from the group consisting of methotrexate, 5-fluorouracil, fluorodeoxyuridine, cytosine arabinoside, 6-mercaptopurine, 6-thioguanine, mechloroethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, thiotepa, mitomycin C, aziridinylbenzoquinone (AZQ), busulfan, carmustine (BCNU), lomustine (CCNU), fotemustine, carboplatin, daunorubicin, doxorubicin or adriamycin, epirubicin, dactinomycin or actinomycin D, mitoxanthrone, amsacrine, tenoposide, etoposide, irinotecan, topotecan, vincristine, vinblastine, vindesine, vinorelbine, taxol, taxotere, and mixtures thereof. ### Claim 18 (depends on 17) The composition according to claim 17, said at least one second therapeutically active substance is doxorubicin. ### Claim 19 (depends on 14) The composition according to claim 14, wherein said first and second therapeutically active substances are suspended in an aqueous agar solution. ### Claim 20 (depends on 14) The composition according to claim 14, wherein said composition does not include any detergent or solvent. ### Claim 21 A kit comprising: at least one first container containing a first therapeutically active substance selected from the group consisting of carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone, and isomers, derivatives or mixtures thereof; and at least one second container containing a second therapeutically active substance which is an antitumoral agent. ### Claim 22 (depends on 21) The kit according to claim 21, wherein said second therapeutically active substance is selected from the group consisting of folate antagonists, antimetabolites, alkylating agents, platinum salts, anthracyclin and intercalating agents, anti-topoisomerases, agents acting on cytoskeleton, bleomycin, asparaginase, and the mixtures thereof. ### Claim 23 (depends on 22) The kit according to claim 22, wherein said second therapeutically active substance is selected from the group consisting of methotrexate, 5-fluorouracil, fluorodeoxyuridine, cytosine arabinoside, 6-mercaptopurine, 6-thioguanine, mechloroethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, thiotepa, mitomycin C, aziridinylbenzoquinone (AZQ), busulfan, carmustine (BCNU), lomustine (CCNU), fotemustine, carboplatin, daunorubicin, doxorubicin or adriamycin, epirubicin, dactinomycin or actinomycin D, mitoxanthrone, amsacrine, tenoposide, etoposide, irinotecan, topotecan, vincristine, vinblastine, vindesine, vinorelbine, taxol, taxotere, and mixtures thereof. ### Claim 24 (depends on 21) The kit according to claim 21, wherein said first therapeutically active substance is thymol, carveol or carvacrol and said second therapeutically active substance is selected from the group consisting of methotrexate, 5-fluorouracil, fluorodeoxyuridine, cytosine arabinoside, 6-mercaptopurine, 6-thioguanine, mechloroethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, thiotepa, mitomycin C, aziridinylbenzoquinone (AZQ), busulfan, carmustine (BCNU), lomustine (CCNU), fotemustine, carboplatin, daunorubicin, doxorubicin or adriamycin, epirubicin, dactinomycin or actinomycin D, mitoxanthrone, amsacrine, tenoposide, etoposide, irinotecan, topotecan, vincristine, vinblastine, vindesine, vinorelbine, taxol, taxotere, and mixtures thereof. ### Claim 25 (depends on 24) The kit according to claim 24, wherein said therapeutically active substance is doxorubicin. ### Claim 26 A method for treating a tumor comprising the simultaneous or sequential administration to a patient having a tumor: at least one first therapeutically active substance selected from the group consisting of carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone and the isomers and derivatives and mixtures thereof; and at least one second therapeutically active substance which is an antitumoral agent. ### Claim 27 (depends on 26) The method according to claim 26, wherein said at least one second therapeutically active substance is selected from the group consisting of folate antagonists, antimetabolites, alkylating agents, platinum salts, anthracyclin and intercalating agents, anti-topoisomerases, agents acting on cytoskeleton, bleomycin, asparaginase, and the mixtures thereof. ### Claim 28 (depends on 27) The method according to claim 27, wherein said at least one second therapeutically active substance is selected from the group consisting of methotrexate, 5-fluorouracil, fluorodeoxyuridine, cytosine arabinoside, 6-mercaptopurine, 6-thioguanine, mechloroethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, thiotepa, mitomycin C, aziridinylbenzoquinone (AZQ), busulfan, carmustine (BCNU), lomustine (CCNU), fotemustine, carboplatin, daunorubicin, doxorubicin or adriamycin, epirubicin, dactinomycin or actinomycin D, mitoxanthrone, amsacrine, tenoposide, etoposide, irinotecan, topotecan, vincristine, vinblastine, vindesine, vinorelbine, taxol, taxotere, and mixtures thereof. ### Claim 29 (depends on 26) The method according to claim 26, wherein said at least one first therapeutically active substance is thymol, carveol or carvacrol and said at least one second therapeutically active substance is selected from the group consisting of methotrexate, 5-fluorouracil, fluorodeoxyuridine, cytosine arabinoside, 6-mercaptopurine, 6-thioguanine, mechloroethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, thiotepa, mitomycin C, aziridinylbenzoquinone (AZQ), busulfan, carmustine (BCNU), lomustine (CCNU), fotemustine, carboplatin, daunorubicin, doxorubicin or adriamycin, epirubicin, dactinomycin or actinomycin D, mitoxanthrone, amsacrine, tenoposide, etoposide, irinotecan, topotecan, vincristine, vinblastine, vindesine, vinorelbine, taxol, taxotere, and mixtures thereof. ### Claim 30 (depends on 29) The method according to claim 29, wherein said at least one second therapeutically active substance is doxorubicin. ### Claim 31 (depends on 26) The method according to claim 26, wherein said method comprises the simultaneous or sequential administration of: between 10 and 200 mg/kg of body weight/day of said first therapeutically active substance; and between 2 and 100 mg/kg of body weight/day of said second therapeutically active substance. ### Claim 32 (depends on 29) The method according to claim 29, wherein said method comprises the simultaneous or sequential administration of: between 10 and 200 mg/kg of body weight/day of said first therapeutically active substance; and between 2 and 100 mg/kg of body weight/day of said second therapeutically active substance.